A
Therapeutic focus
PepTiDa develops peptide and peptidomimetic molecules designed to modulate disease-relevant biological pathways involved in neuronal injury and synaptic dysfunction.
Innovative biotech startup · University of Milan spin-off
Peptide science for brain diseases.
PepTiDa develops peptide and peptidomimetic approaches designed to address biological mechanisms involved in neuronal injury, synaptic dysfunction and neurodegeneration.
The company is currently advancing its research platform from preclinical science toward translational and regulatory-ready development.
Peptide-based neurobiology
Brainfocus on mechanisms involved in neuronal injury and neurodegeneration
Peptidesdesign of peptide and peptidomimetic therapeutic candidates
Biologyintegration of molecular, computational and experimental expertise
IPresearch platform supported by a dedicated intellectual property strategy
Developing peptide and peptidomimetic therapeutics for brain diseases.
PepTiDa is an innovative biotech startup and University of Milan spin-off focused on highly targeted peptide-based approaches for severe brain diseases, with a particular focus on neurodegeneration and ischemic injury.
B
Integrated discovery approach
The company combines computational modeling, protein-structure expertise and laboratory validation to design and characterize targeted therapeutic candidates.
C
Translational ambition
PepTiDa aims to translate advanced neuroscience into clinically relevant treatments, moving from robust preclinical evidence toward regulatory-grade development.
Understanding shared mechanisms across brain diseases.
Many brain diseases involve converging biological processes, including neuronal stress, synaptic impairment, inflammation and progressive tissue damage. PepTiDa focuses on selected molecular pathways that may help protect neuronal structure and function.
01
Targeted molecular modulation
PepTiDa investigates highly selective peptide-based approaches designed to interact with disease-relevant molecular pathways in the nervous system.
02
Translational biology
The scientific strategy integrates target biology, experimental validation and translational readouts to support future development decisions.
03
Brain disease focus
The research platform is relevant to acute and chronic brain diseases where neuronal injury and synaptic dysfunction play a central role.
From molecular design to translational development.
PepTiDa combines peptide science, protein-structure expertise and experimental biology to develop therapeutic candidates for diseases of the nervous system.
Peptide design+Target biology
Preclinical validation=Translational path
Design
Computational and structural biology support the design and optimization of peptide and peptidomimetic candidates.
Validate
Experimental work is used to assess biological relevance, selectivity and translational potential.
Develop
Promising candidates are advanced through preclinical packages aligned with regulatory and partnering expectations.
Partner
The company is open to scientific, translational and industrial collaborations supporting platform development.
IP
Intellectual property strategy
PepTiDa’s research and development activities are supported by a dedicated intellectual property strategy covering its peptide-based innovation.
SCI
Academic roots
The company originates from university research and builds on scientific expertise in neuroscience, molecular biology and peptide design.
TR
Translation-oriented
The development path is designed to move selected candidates from research evidence toward regulatory-grade and partnership-ready packages.
Roadmap focused on responsible translational development.
The next development phase is designed to strengthen the research platform, characterize selected candidates and prepare a development path suitable for future regulatory and industrial discussions.
Step 1
Research consolidation
Further characterization of peptide candidates, target biology and disease-relevant experimental models.
Step 2
Preclinical package
Progressive development of pharmacology, formulation, manufacturability and safety-oriented evidence.
Step 3
Regulatory planning
Preparation of a structured development plan aligned with future regulatory interaction and clinical translation.
Step 4
Partnership readiness
Creation of a scientific and development package suitable for collaborations, investment and industrial partnering.
Scientific depth, strengthened by biotech execution capabilities.
PepTiDa combines neuroscience expertise, peptide and protein-structure capabilities, executive leadership and a senior expert network across business development, clinical development, regulatory strategy, CMC and quality.
Michela Pantaleoni
Chief Executive Officer
Executive profile with 20+ years across pharma and biotech, combining strategy, market access, asset valuation, fundraising and business execution.
Tiziana Borsello
Chief Scientific Officer · Founder
Professor of Human Anatomy, University of Milan. 35+ years in neuroscience, neuronal death and neuroprotection research, with experience at the Mario Negri Institute and international scientific collaborations.
Massimiliano Di Cicco
Chief Business Officer
International executive and advisor with 20+ years in biotech, pharma and MedTech across strategy, finance, commercial development, BD and fundraising.
Domenico Raimondo
Senior Scientific Specialist
Specialist in protein structure, bioinformatics and molecular modeling, supporting the characterization of protein interactions and peptide design.
Scientific contributors
Computational · Molecular · Preclinical
Researchers and collaborators support molecular biology, computational analysis, recombinant protein production and preclinical experimental work.
Business & strategic advisors
Healthcare · Biotech · Investment
Senior advisors contribute experience in healthcare entrepreneurship, biotech strategy, partnerships and investor-readiness.
Senior expert network
External experts support PepTiDa across the capabilities required to progress from preclinical evidence to a regulatory- and partnering-ready package.
Regulatory strategy
Clinical development
Translational biomarkers
CMC
Quality
Preclinical execution
Business development
Fundraising
News and recognition
Selected recognitions and institutional milestones supporting PepTiDa’s innovation journey.
WIPO Global Awards recognition
PepTiDa has been recognized by WIPO among leading SMEs and startups using intellectual property to drive innovation and address real-world needs.
Building a peptide-based platform for brain diseases.
Open to scientific collaborations, translational partnerships and investor conversations supporting the next phase of PepTiDa’s development.